# Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery

> **NCT02262325** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIA Non-small Cell Lung Cancer
- Stage IIB Non-small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** hypofractionated radiation therapy
- **DRUG:** cisplatin
- **DRUG:** etoposide
- **RADIATION:** 3-dimensional conformal radiation therapy
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02262325
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-08
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-04-15
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262325, "Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02262325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*